Shopping Cart
Remove All
Your shopping cart is currently empty
Labetuzumab govitecan
(Synonyms: Labetuzumab-SN38, IMMU-130, IMMU130, IMMU 130, hMN14-SN38, hMN-14-SN-38) Copy Product Info
🥰Excellent
Synonyms: Labetuzumab-SN38, IMMU-130, IMMU130, IMMU 130, hMN14-SN38, hMN-14-SN-38
Catalog No. T25593 Copy Product Info
🥰Excellent
Labetuzumab govitecan is an antibody-drug conjugate (ADC) targeting CEACAM5, composed of the labetuzumab antibody, the payload SN-38, and a pH-sensitive linker. It can be used in research on malignant tumors such as colorectal cancer.
Labetuzumab govitecan
Cas No. 1469876-18-3
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $622 | 2-4 weeks | 2-4 weeks | |
| 5 mg | $1,620 | 2-4 weeks | 2-4 weeks |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Labetuzumab govitecan is an antibody-drug conjugate (ADC) targeting CEACAM5, composed of the labetuzumab antibody, the payload SN-38, and a pH-sensitive linker. It can be used in research on malignant tumors such as colorectal cancer. |
| In vivo | Labetuzumab govitecan administered intraperitoneally at a total dose of 1.0 mg prolongs the median survival in a mouse model of GW-39 lung metastasis. Labetuzumab govitecan administered intraperitoneally at 25 mg/kg twice weekly for 4 weeks prolongs the median survival in a LS174T subcutaneous xenograft nude mouse model [2]. |
| Synonyms | Labetuzumab-SN38, IMMU-130, IMMU130, IMMU 130, hMN14-SN38, hMN-14-SN-38 |
| Reactivity | Human |
| Application | Functional assay |
| Antibody Type | Monoclonal, ADC |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | SN38 |
| Gene ID | |
| Uniprot ID | |
| Target | CEACAM5/CEA/CD66e |
| Cas No. | 1469876-18-3 |
| Relative Density. | no data available |
| Isotype | IgG1 |
| Storage | Store at low temperature Store at -20°C Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: Labetuzumab govitecan in vivo
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.